Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:32 AM
Ignite Modification Date:
2025-12-25 @ 2:32 AM
NCT ID:
NCT00322634
Eligibility Criteria:
Inclusion Criteria:
1. All patients must be at least 18 years of age
2. All patients must have documented incurable metastatic cancer
3. All patients must have exhausted any treatments which are known to prolong survival in their disease, or have elected not to receive further life-prolonging therapy. Specifically, patients with the following are eligible:
1. Non-small cell lung cancer patients after third systemic therapy
2. Small cell lung cancer patients after second systemic therapy
3. Breast cancer patients after third cytotoxic therapy (does not include hormonal therapy)
4. Colorectal cancer patients after second systemic therapy
5. Hormone refractory prostate cancer patients after first cytotoxic therapy
6. Cancer of unknown primary
7. Pancreatic cancer patients after first systemic therapy
4. The use of systemic (chemotherapy, immunotherapy) or local treatments (XRT) for palliation of symptoms is allowed
5. Patients with a history of previous cancers are allowed
6. Patients with a history of other significant disease (e.g. heart disease, COPD, etc.) are allowed
7. All patients must sign informed consent
Exclusion Criteria:
1. Patients with acute or chronic leukemia, Hodgkin's disease, or non-Hodgkins lymphoma are excluded
2. Patients who do not sign informed consent are excluded
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00322634
Study Brief:
Protocol Section:
NCT00322634